CN Mobile Logo

Search form


CA4P Gets Orphan Drug Status

CA4P Gets Orphan Drug Status

Waltham, Mass—The FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin and paclitaxel, the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.